Blackstone Life Sciences
Evan L. Rachlin, MD, is a principal in Blackstone Life Sciences and focused on health care investing. Prior to Blackstone, he was head of strategy at Moderna, which completed the largest biotech IPO in history in 2018. Previously, Dr. Rachlin worked at Bain Capital, McKinsey & Company and Pfizer. He is currently on the board of FerGene. Dr. Rachlin earned an MD from Harvard Medical School, MBA from Harvard Business School, and AB magna cumlaude from Harvard College with a concentration in Biochemistry and a citation in Japanese.